Now in its 16th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena.

DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim….’Turning Science into Business’.

DDW examines the advances in new science and technology with a view to the commercial implications of implementing those advances and whether they can truly bring benefits to the drug discovery and development process with the goal of reducing costs and attrition rates whilst ultimately, bringing new and effective therapeutics to the market faster.

DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level allowing them to understand the new technologies and strategies and the impact they can have on their particular segments of the business.

Scientist and CEO alike can profit from the uncomplicated style of the editorial and, furthermore, gain a wealth of information on a diverse range of life science topics. In our articles, we challenge the industry to look at new ways of overcoming discovery bottlenecks, embrace new technologies, form relationships with discovery partners and build next generation technology platforms. power.

Publisher and Editor in chief: Robert Jordan

RJ Communications Ltd
39 Vineyard Patrh
London SW14 8ET
Tel +44 (0)208 487 5656